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Our study reveals a non-canonical role for CCL2
in modulating non-macrophage, myeloid-derived
suppressor cells (MDSCs) and shaping a tumor-
permissive microenvironment during colon cancer
development. We found that intratumoral CCL2
levels increased in patients with colitis-associated
colorectal cancer (CRC), adenocarcinomas, and
adenomas. Deletion of CCL2 blocked progression
from dysplasia to adenocarcinoma and reduced the
number of colonic MDSCs in a spontaneous mouse
model of colitis-associated CRC. In a transplantable
mousemodel of adenocarcinoma and anAPC-driven
adenoma model, CCL2 fostered MDSC accumula-
tion in evolving colonic tumors and enhanced
polymorphonuclear (PMN)-MDSC immunosuppres-
sive features. Mechanistically, CCL2 regulated
T cell suppression of PMN-MDSCs in a STAT3-medi-
ated manner. Furthermore, CCL2 neutralization
decreased tumor numbers and MDSC accumulation
and function. Collectively, our experiments support
that perturbing CCL2 and targeting MDSCs may
afford therapeutic opportunities for colon cancer
interception and prevention.INTRODUCTION
Colorectal cancer (CRC) is the second leading cause of cancer
deaths in the United States (Tenesa and Dunlop, 2009). CRC in-
cludes hereditary, sporadic, and colitis-associated colon can-
cer. Inflammatory bowel disease (IBD) is associated with an
increased risk of developing IBD-associated CRC (Itzkowitz,244 Cell Reports 12, 244–257, July 14, 2015 ª2015 The Authors2003). Chronic inflammation plays a key role in tumor initiation
in colitis-associated CRC. Although other types of CRC
develop without any signs of macroscopic inflammation, robust
infiltration of multiple immune cells is a common feature of spo-
radic CRC.
Immune cells play a central role in the tumor microenviron-
ment (Hanahan and Coussens, 2012). CRC involves imbal-
anced Th1/Th17/Th2 responses (Galon et al., 2013), altered
innate lymphoid cell activity (Pearson et al., 2012), and
enhanced immunosuppressive regulatory T cells and tumor-
associated macrophages (TAMs) (Kang et al., 2010). Accumu-
lating evidence supports that myeloid-derived suppressor
cells (MDSCs) contribute to cancer immune evasion by sup-
pressing T cell anti-tumor functions and modulating innate im-
mune responses (Gabrilovich and Nagaraj, 2009). MDSCs
comprise a heterogeneous population of immature myeloid
cells characterized by co-expression of CD11b and Gr-1 and
lack features of mature macrophages and dendritic cells in
tumor-bearing mice (Gabrilovich et al., 2012). MDSCs can be
divided into two distinct sub-populations: monocytic MDSCs
(Mo-MDSCs) and polymorphonuclear (PMN)-MDSCs, also
known as granulocytic (G)-MDSCs (Gabrilovich et al., 2012).
These two subsets differ in their gene expression profiles and
immunosuppressive activities (Gabrilovich and Nagaraj, 2009).
In many cancers, including CRC, blood MDSC numbers corre-
late with stage and metastatic burden (Diaz-Montero et al.,
2009). However, factors regulating MDSC subset accumulation
and MDSC’s distinct contributions to CRC development remain
underexplored.
Chemokines, which recruit immune cells to inflamed sites,
contribute to the pathogenesis of colitis and colon cancer.
CCL2, a member of the C-C chemokine family, regulates the
recruitment of myeloid cells into inflamed sites and tumors.
CCL2-mediated macrophage recruitment promotes tumor
growth, progression, and metastasis in breast, ovarian, and
prostate cancers (Fader et al., 2010; Qian et al., 2011; Zhang
Figure 1. CCL2 Levels Increase with Neoplastic Progression in Human and Mouse Colitis-Associated CRC
(A) CCL2 expression levels in 11 human colitis-associated colorectal dysplasia and adenocarcinoma (ACA) cases. Left panel: total CCL2+ area from five fields
(objective 403) plotted for each case. Areas for quantification were no colitis (normal), colitis (no dysplasia/ACA), dysplasia, and ACA. Symbols are color-coded to
track samples. Right panel: representative images of CCL2 immunostaining in human colon samples. Yellow triangles, epithelial cells; red triangles, infiltrating
immune cells. Scale bar, 50 mm.
(B) CCL2 colonic protein levels from T-bet/ Rag2/mice across the neoplastic continuum, quantitated by ELISA. Mean ± SEM with age and number of mice
per group shown.
(C) Prevalence of dysplasia and neoplasia in Ccl2/ T-bet/ Rag2/ and T-bet/ Rag2/ mice monitored by mouse age. Symbols represent data from
individual mice, with color-coding indicating age in months.
*p < 0.05, **p < 0.01, and ***p < 0.001 (unpaired, two-tailed Student’s t test). See also Figure S1.et al., 2010). Monocytes recruited to tumors through the CCL2-
CCR2 axis are polarized to TAMs, contributing to tumor cell sur-
vival (McClellan et al., 2012). Two prior studies suggested that
CCL2 increased colon tumor numbers in mice through a
CCL2-CCR2-dependent recruitment of myeloid cells (McClellan
et al., 2012; Popivanova et al., 2009). The complete functional
repertoire of colonic CCL2 remains unclear, and whether colonic
CCL2 expression is elevated in human colitis-associated CRC is
unknown.
We identify a role for CCL2 in influencing MDSC accumulation
and function in the colon and tumor microenvironment during
colon carcinogenesis. Using human colitis-associated CRC,
sporadic CRC, and adenomas in conjunction with three distinct
and complementary mouse models of colorectal carcinogen-
esis, we elucidate cellular and molecular mechanisms by which
CCL2 affects PMN-MDSC accumulation and immunosuppres-
sive function during this neoplastic process. Together, our re-
sults highlight a pro-neoplastic role for CCL2 in regulating
MDSC accumulation and the importance of MDSCs and CCL2
in the development of CRC.RESULTS
Increased Colonic CCL2 Expression Is Associated with
Neoplastic Progression in Human and Mouse Colitis-
Associated CRC
Although elevated CCL2 expression has been linked to tumor
progression by myeloid cell influxes via CCR2-mediated altered
endothelial vascular permeability (Wolf et al., 2012) and CCL2
expression has been mapped to specific cell types (Tsuyada
and Wang, 2013), colonic CCL2 levels have not been assessed
across the neoplastic continuum. To assess CCL2 levels in hu-
man colitis-associated CRC, we used immunohistochemistry
and semiquantitative histomorphometry to measure the total
CCL2+ area in colonic tissues in 11 cases of human IBD with
active colitis, dysplasia, and adenocarcinoma (ACA). CCL2
expression was increased in regions of active colitis or dysplasia
versus no colitis (normal) (p < 0.01 and p < 0.05, respectively).
CCL2 levels were significantly higher in areas of ACA versus
active colitis or dysplasia (p < 0.05) (Figures 1A and S1A).
CCL2 staining was both clustered and diffuse in the majority ofCell Reports 12, 244–257, July 14, 2015 ª2015 The Authors 245
tissues with ACA involvement, and both epithelial cells and infil-
trating lamina propria immune cells appear to express CCL2
(Figure 1A, right panel). The association between increasing
CCL2 levels and ACA in human colitis-associated neoplasia
prompted us to evaluate the function of CCL2 in colitis-associ-
ated CRC in mice.
T-bet/ Rag2/ mice develop colonic dysplasia and ACA,
which bear similarities to human colitis-associated dysplasia
and CRC (Garrett et al., 2009). We determined the colonic
CCL2 expression levels in BALB/c T-bet/ Rag2/ mice with
no dysplasia, low-grade dysplasia (LGD), high-grade dysplasia
(HGD), and ACA. The BALB/c background was selected, as co-
litis penetrance and HGD and ACA frequency are higher
compared with the C57BL/6 background (Ermann et al., 2011;
Garrett et al., 2009). Similar to results of human colitis-associ-
ated CRC patients, CCL2 levels increased in T-bet/ Rag2/
mice during colorectal carcinogenesis and were elevated in
ACA-involved tissue (p < 0.0001 in all cases) (Figure 1B). Prior
studies examining CCL2 function in colitis-associated CRC
have used mice with altered CCR2 expression (Popivanova
et al., 2009). However, CCR2, like many chemokine receptors,
can bind several chemokines (CCL2, CCL7, CCL8, CCL12,
CCL13, and CCL16; Zlotnik and Yoshie, 2012), and CCL2 can
bind CCR2, CCR3, and CCR4 (Lazennec and Richmond, 2010;
Schall and Proudfoot, 2011). To delineate CCL2’s role in coli-
tis-associated neoplastic progression, we generated BALB/c
Ccl2/ T-bet/ Rag2/ mice and monitored them for the
development of dysplasia and ACA for over a year, guided by
prior observations of dysplasia and cancer frequencies in
T-bet/ Rag2/ mice (Garrett et al., 2009). Ccl2/ T-bet/
Rag2/ (n = 106) and T-bet/ Rag2/ (n = 142) mice devel-
oped colitis of similar severity over a similar time course (Figures
S1B and S1C), and Ccl2/ T-bet/ Rag2/ mice succumbed
with poor body condition, as did T-bet/Rag2/mice, over the
same time frame. However, Ccl2/ T-bet/ Rag2/ mice did
not develop ACA, and the frequency of dysplasia was markedly
lower in Ccl2/ T-bet/ Rag2/ mice than in T-bet/
Rag2/ mice (LGD 7.55% versus 30.28%, HGD 5.66% versus
45.77%) (Figure 1C). These observations suggest that colonic
CCL2 may function in tumor initiation or as a neoplastic factor
contributing to progression from dysplasia to ACA in colitis-
associated CRC.
CCL2 Influences Colonic MDSC Accumulation and
Immunosuppressive Features in Pre-malignant Stages
of Colorectal Carcinogenesis
Chronic inflammation contributes to tumor initiation in colitis-
associated CRC, and infiltration of immune cells, specifically
CD11b+ myeloid cells, plays a central role in carcinogenesis.
CCL2 recruits myeloid cells, including TAMs, and influences their
polarization in the tissuemicroenvironment (Sica andMantovani,
2012). Given the elevated levels of CCL2 in T-bet/ Rag2/
colons during carcinogenesis, we examined whether CCL2
affected recruitment of colonic myeloid cells, including TAMs.
AlthoughCcl2/ T-bet/Rag2/mice do not develop cancer,
examining colonic tissues from T-bet/ Rag2/ and Ccl2/
T-bet/ Rag2/ mice would enable us to determine if CCL2
acts on tumor-promoting myeloid cells in the colon during the246 Cell Reports 12, 244–257, July 14, 2015 ª2015 The Authorsearly stages of the neoplastic process. We analyzed colonic
myeloid cells in T-bet/ Rag2/ andCcl2/ T-bet/ Rag2/
mice using a flow cytometry scheme andmarkers that have been
previously validated for the study of tumor-associated myeloid
cells (Figures 2A and 2B) (Franklin et al., 2014; Youn et al.,
2008). There were no significant differences in total CD11b+
cell, CD11b+Gr-1myeloid cell (Figures 2A, 2B, and S2A, popu-
lation I), or M2-like TAM (CD11b+Gr-1F4/80+MMR+) numbers
between T-bet/ Rag2/ and Ccl2/ T-bet/ Rag2/ mice
(Figure 2C). Given these data, we next investigated whether
CCL2 influences other intratumoral myeloid cells.
MDSCs suppress anti-tumor immune responses and promote
tumor growth andmetastasis (Gabrilovich et al., 2012). The func-
tions and phenotypes of splenic MDSCs have been explored in
many mouse solid tumor models, however, the functions and
features of intestinal MDSCs during colonic carcinogenesis
remain under-investigated. We queried whether CCL2 affected
colonic MDSC accumulation and found that CD11b+Gr-1+
MDSC numbers increased 2-fold in the colons of T-bet/
Rag2/ mice versus Ccl2/ T-bet/ Rag2/ mice before
dysplasia was detectable and increased 4-fold in LGD (p <
0.01 and p < 0.05, respectively) (Figure 2C). Prior to the develop-
ment of dysplasia and in LGD, Mo-MDSCs (Figures 2A, 2B, and
S2A, population II) and PMN-MDSCs (Figures 2A, 2B, and S2A,
population III) increased 2-fold in T-bet/ Rag2/ mice versus
Ccl2/ T-bet/Rag2/mice, p < 0.05 (Figure 2C). There were
also differences in PMN-MDSC and Mo-MDSC numbers in HGD
between T-bet/ Rag2/ and Ccl2/ T-bet/ Rag2/mice,
although the number of mice in each group was small, as few
Ccl2/ T-bet/ Rag2/ mice develop HGD (Figure S2B).
Recent studies suggest that Arginase1 (Arg1), IL-10, and reac-
tive oxygen species (ROS) underlie MDSC immunosuppressive
activities (Gabrilovich and Nagaraj, 2009). S100A8 and S100A9
also promote MDSC accumulation and enhance their suppres-
sive activity (Sinha et al., 2008). To test if CCL2 alters expression
of these factors, we isolated colonic MDSCs from both T-bet/
Rag2/ and Ccl2/ T-bet/ Rag2/ mice with either no
dysplasia or LGD. Arginase1 and Il10 expression were signifi-
cantly decreased in colonic MDSCs inCcl2/ T-bet/Rag2/
mice in the absence of dysplasia and in LGD (Figure 2D). In
Ccl2/ T-bet/ Rag2/ mice, we also observed significant
downregulation of S100A8 and S100A9 as well as gp91phox, a
component of the NADPH oxidase (Nox2) complex, which is
necessary for colonic MDSC ROS production (Figure 2D). Our
data support that CCL2 drives MDSC accumulation in the colon
as dysplasia develops and that CCL2-driven MDSC functional
features, in the absence of adaptive immune responses,
contribute to a tumor-permissive microenvironment in colitis-
associated CRC development.
CCL2 Enhances Tumor MDSC Accumulation during
Colonic ACA Growth
Cancer cells can produce CCL2, leading to recruitment of tumor-
promoting myeloid cells into the tumor during carcinogenesis.
qRT-PCR analysis of 43 healthy and CRC patients (nine or ten
subjects per CRC stage) suggested that CCL2 transcripts were
increased in CRC versus normal tissues (Wolf et al., 2012).
Based on these data, we sought to confirm that CCL2 protein
Figure 2. CCL2 Induces Colonic MDSC Accumulation and Alters MDSC Gene Expression in Colitis-Associated Pre-malignancy
Colonic myeloid cells were isolated from Ccl2/ T-bet/ Rag2/ and T-bet/ Rag2/ mice with or without low-grade dysplasia (LGD).
(A) The gating strategy for myeloid cell subset identification. Following a leukocytes gate (CD45+), cells are further gated for CD11b+ myeloid cells only and
CD11b+Gr-1+ MDSCs or CD11b+Gr-1 macrophages (population I). Ly6C and Ly6G were used to distinguish Mo-MDSCs (population II) and PMN-MDSCs
(population III). The F4/80 and MMR flow plot was used to identify tumor-promoting macrophages (TAMs and M2-like TAMs).
(B) Flow cytometric analysis of populations I-III as gated in (A). Data are representative of at least three independent experiments.
(C) Quantification of select colonic myeloid cells by flow cytometry. Symbols represent data from individual mice, and bars show the mean.
(D) Colonic MDSC sorted from Ccl2/T-bet/ Rag2/ and T-bet/ Rag2/ mice and Arginase1 and Il10 (C), S100A8, S100A9, gp91phox, and iNOS (D)
expression levels were evaluated by qRT-PCR. Symbols represent data from individual mice. Data are from age-matched (4- to 5-month old) and littermate mice.
*p < 0.05, **p < 0.01, and ***p < 0.001 (unpaired, two-tailed Student’s t test). See also Figure S2.levels were increased in human colon ACA. Using human tissue
microarrays, which included both normal colon tissue (n = 29)
and ACA (n = 119), we found that CCL2 levels significantly
increased in the ACA samples (Figure 3A).
To examine whether cancer-cell-produced CCL2 affects
accumulation and function of MDSC populations in colonic
ACAs, we employed the Colon-26 colonic ACA transplantation
model (Ohana et al., 2003), as ACAs do not develop in Ccl2/
T-bet/ Rag2/ mice. We perturbed CCL2 expression in
Colon-26 cells by generating Colon-26 cell lines with stable
short-hairpin RNA (shRNA) knockdown of their endogenous
Ccl2 and shRNA for GFP (shControl) as a control. We verified
knockdown by CCL2 protein determinations from supernatants
of the shCCL2 Colon-26 cell lines and selected one stable cell
line (shCCL2) (Figure S3A). We measured tumor volume and
size and counted the number of intratumoral MDSCs at day 14
after subcutaneous injection of shControl and shCCL2 stable
cell lines. This time point was selected to comply with humane
endpoints governing tumor size. shControl tumors were consid-
erably larger (nearly 9-fold) than shCCL2 tumors in volume andsize (Figure 3B) (p < 0.0001); however, there was no significant
difference in in vitro proliferation between shControl and shCCL2
Colon-26 cells (Figure S3B). As expected, we observed higher
intratumoral CCL2 levels in shControl tumor as compared to
shCCL2 tumor (Figure S3C).
We examined CD11b+Gr-1+ MDSC accumulation in shControl
and shCCL2 tumors using immunofluorescence microscopy
(Figure 3C). Next, we characterized the intratumoral myeloid
cell populations using flow cytometry (Figures 3D and 3E) as in
Figure 2. MDSC numbers increased over 4-fold (p < 0.0001)
and Mo-MDSC and PMN-MDSC subpopulations accumulated
over 2-fold in the shControl tumors compared to those from
shCCL2 tumors (p < 0.05 and p < 0.001, respectively) when
normalized by tumor weight (Figure 3F). To confirm if CCL2
was driving increased tumor growth and MDSC accumulation,
we performed ‘‘add-back’’ experiments wherein we intratumor-
ally injected recombinant CCL2 or PBS into shCCL2 tumor-
bearing mice at day 5 after injection of shCCL2 Colon-26 cells
and examined tumor volume and the number of MDSCs at day
14 after injection. Tumor volume was significantly increased inCell Reports 12, 244–257, July 14, 2015 ª2015 The Authors 247
Figure 3. CCL2 Levels Increase in Human Sporadic CRC and CCL2 Enhances Tumor MDSC Accumulation during Colonic Adenocarcinoma
Growth
(A) CCL2 levels in human colon adenocarcinoma tissue microarrays (normal, n = 29; adenocarcinoma, n = 119). Representative images are shown. Scale
bar, 500 mm.
(B–F) Colon26shGFP (shControl) or Colon26shCCL2-2 (shCCL2) cells were subcutaneously injected into BALB/c mice and tumor growth evaluated at day14.
(B) Representative images of tumor-bearing mice (upper panel) and tumor volumes (lower panel). (C) Representative immunofluorescence microscopy images.
Tumors were stained with DAPI and for CD11b andGr-1; single-channel and pseudocolored images. Scale bar, 50 mm. (D) Flow cytometry gating strategy and (E)
analysis of intratumoral Mo-MDSCs, PMN-MDSCs, and CD11b+Gr-1 myeloid cells. (F) Intratumoral MDSC, PMN-MDSC, and Mo-MDSC numbers from
shControl versus shCCL2 tumor-bearing mice with cell numbers normalized by tumor weight. Symbols represent individual mice.
(G and H) shCCL2 cells were subcutaneously injected into mice and recombinant CCL2 or PBS was intratumorally injected into shCCL2 tumor-bearing mice at
day 5 and day 12. Tumor volumes at day 19 (G). Intratumoral MDSC, PMN-MDSC, and Mo-MDSC numbers normalized by tumor weight (H).
(I) Intratumoral TAM and M2-like-TAM cell numbers.
(J) shCCL2 cells were subcutaneously injected into mice, and then sorted TAMs or MDSCs from spleens of shControl tumor-bearing mice were intratumorally
injected into shCCL2 tumor-bearing mice at day 5. Tumor volumes were evaluated at day 14.
All data reflect at least three independent experiments. *p < 0.05, **p < 0.01, and ***p < 0.001 (unpaired, two-tailed Student’s t test). See also Figure S3.shCCL2 tumor-bearing mice injected with recombinant CCL2
(p < 0.001) (Figure 3G), as were intratumoral MDSC and PMN-
MDSC numbers (p < 0.05) (Figure 3H).
To address if CCL2 affects other myeloid cells in the tumor
microenvironment, we examined tumor-promoting macro-
phages, including TAMs (CD11b+Gr-1F4/80+) and M2-like
TAMs (CD11b+Gr-1F4/80+MMR+). Tumor-promoting macro-
phages significantly increased in the shControl tumors but were248 Cell Reports 12, 244–257, July 14, 2015 ª2015 The Authorssignificantly fewer than the MDSC numbers (Figure 3I). There
were no statistically significant differences in tumor-associated
neutrophils (CD11b+Ly6G+) between shControl and shCCL2 tu-
mor-bearing mice (Figure S3D) (Fridlender et al., 2009).
To determine if MDSCs or TAMs contribute to tumor
growth, we sorted splenic MDSCs and TAMs from shControl
tumor-bearing mice at day 14 and intratumorally injected the
cells into shCCL2 tumor-bearing mice at day 5. shCCL2
Figure 4. CCL2 Promotes T Cell Suppression via PMN-MDSCs
(A and B) T cell proliferation assays. Intratumoral PMN-MDSCs andMo-MDSCswere sorted from shControl or shCCL2 tumor-bearingmice. (A) CellTrace-labeled
splenic CD4+T cells from syngeneic mice were coincubated for 3 days with sorted intratumoral PMN-MDSCs or Mo-MDSCs. Representative flow cytometric
analyses of activated or nonactivated CD4+ T cell proliferation and activated CD4+ T cell in the presence of sorted MDSCs are shown. Bar graph shows mean ±
SEM of three independent experiments. (B) CellTrace-labeled splenic CD8+T cells were coincubated for 3 days with sorted intratumoral PMN-MDSCs or
Mo-MDSCs.
(C and D) Suppressive mechanisms of PMN-MDSCs or Mo-MDSCs on TCR components. z chain expression (C) and nitrotyrosine levels (D) of CD4+ T cells or
CD8+ T cells coincubated with sorted intratumoral PMN-MDSCs or Mo-MDSCs were measured by flow cytometry. Data, shown as MFI ± SEM, reflect three
independent experiments.
*p < 0.05, **p < 0.01, and ***p < 0.001 (unpaired, two-tailed Student’s t test). See also Figure S4.tumor-bearingmice injected withMDSCs from shControl tumors
showed significantly increased tumor growth as compared with
mice receiving TAMs or PBS (Figure 3J). These results indicate
that CCL2 drives MDSC accumulation in the tumor microenvi-
ronment and support that MDSCs contribute to increased tumor
growth.
CCL2 Modulates PMN-MDSC Suppression of T Cells by
Increasing PMN-MDSC ROS and Enhancing PMN-
MDSC-Mediated Decreases in T Cell Receptor z Chain
MDSCs suppress T cell activation (Gabrilovich and Nagaraj,
2009). While there are some similarities among MDSCs (both
PMN-MDSCs and Mo-MDSCs), neutrophils, and inflammatory
monocytes, a principal difference is that PMN-MDSCs and Mo-
MDSCs suppress T cell proliferation but neutrophils and inflam-
matory monocytes do not (Damuzzo et al., 2015; Gabrilovich
et al., 2012). Also, while neutrophils from naive tumor-free mice
and intratumoral PMN-MDSCs show similar Ly6C and Ly6G
staining, their CCR2 expression differs greatly (Figure S4A). To
evaluate the immunosuppressive activity ofMDSCs and to deter-mine whether CCL2 in the tumor microenvironment enhances
MDSC-mediated suppression of T cells, we examined the inhibi-
tion of PMN-MDSCs and Mo-MDSCs on T cell proliferation
in vitro. PMN-MDSCs or Mo-MDSCs isolated from shControl
and shCCL2 tumors were co-incubated with syngeneic CD4+ or
CD8+ T cells, and proliferation of T cells was analyzed by flow
cytometry.PMN-MDSCs,but notMo-MDSCs, fromshControl tu-
mors were more effective in suppressing both CD4+ and CD8+
T cell proliferation than PMN-MDSCs from shCCL2 tumors (p <
0.001 and p < 0.05, respectively) (Figures 4A and 4B). We also
examinedwhetherCCL2 had similar effects on intratumoralmac-
rophages, including TAMs and M2-like TAMs. Neither TAMs nor
M2-like TAMs from shControl tumors inhibited CD4+ T cell prolif-
eration (Figure S4B). Also, there was no significant difference in
the suppression of CD4+ and CD8+ T cell proliferation with tu-
mor-promoting macrophages populations (TAMs and M2-like
TAMs) from shControl and shCCL2 tumors (Figure S4C).
MDSC-mediated suppression of T cells has been associated
with altered T cell receptor (TCR) function, ranging from
decreased TCR z chain expression (Ezernitchi et al., 2006;Cell Reports 12, 244–257, July 14, 2015 ª2015 The Authors 249
Figure 5. CCL2 Enhances Function of PMN-
MDSCs
(A) Representative images from shControl and
shCCL2 tumors stained with DAPI, and for ROS
(Hydro-Cy3), CD11b, and Gr-1. Single-channel
pseudocolored and merged images (left panel).
Scale bar, 20 mm. Microscopy-based quantitation
of MFI of ROS per MDSC from shControl and
shCCL2 tumors is shown (right panel).
(B) ROS production levels in intratumoral PMN-
MDSCs and Mo-MDSCs from shControl or
shCCL2 tumor-bearing mice were detected by
DCFDA staining and flow cytometry. Data are
shown as MFI ± SEM.
(C and D) Expression levels of gp91phox (C),
S100A8 and S100A9 (D) in intratumoral PMN-
MDSCs and Mo-MDSCs from shControl or
shCCL2 tumors measured by RT-qPCR. Mean
relative expression ± SEM are shown.
(E) Expression of iNOS levels (MFI) in sorted in-
tratumoral PMN-MDSCs or Mo-MDSCs from
shControl or shCCL2 tumor-bearing mice mea-
sured by flow cytometry.
(F) Expression of PD-L1 in sorted tumor-derived
PMN-MDSCs or Mo-MDSCs from shControl or
shCCL2 tumor-bearing mice measured by flow
cytometry. Data are shown as MFI ± SEM.
All data reflect three independent experiments.
*p < 0.05, **p < 0.01, and ****p < 0.0001 (unpaired,
two-tailed Student’s t test). See also Figure S5.Sade-Feldman et al., 2013) to the nitration of tyrosines in the TCR
signaling complex and subsequent desensitization of the TCR
(Nagaraj et al., 2007). To determine whether CCL2 influences
MDSC-mediated decreased TCR z chain expression and tyro-
sine nitration, we co-cultured PMN-MDSCs or Mo-MDSCs iso-
lated from shControl and shCCL2 tumors with CD4+ T cells
and CD8+ T cells and assessed T cell z chain expression and
tyrosine nitration. PMN-MDSCs, but not Mo-MDSCs, isolated
from shControl tumors resulted in decreased TCR z chain
expression in CD4+ T cells as compared to PMN-MDSCs from
shCCL2 tumor (p < 0.001), whereas this was not observed with
CD8+ T cells (Figure 4C). In contrast, expression of nitrotyrosine
significantly increased with CD8+ T cells co-cultured with PMN-
MDSCs from shControl, but there was no significant induction of
tyrosine nitration in CD4+ T cells co-cultured with PMN-MDSCs
(Figure 4D).
MDSC immunosuppressive activity has been linked to
MDSC Arg1 expression and nitric oxide and ROS production
(Gabrilovich et al., 2012). PMN-MDSCs exert T cell inhibition
mainly through ROS production, whereas Mo-MDSCs suppress
T cells predominantly via the enzymes Arg1 and inducible nitric
oxide synthase (iNOS) and through the production of reactive
nitrogen species (Gabrilovich and Nagaraj, 2009; Movahedi
et al., 2008; Youn et al., 2008). Given that the suppressive activity
of PMN-MDSCs increased in shControl tumors (Figure 4A), we
examined ROS levels in shControl and shCCL2 tumors by
Hydro-Cy3 staining (Leoni et al., 2013). Immunofluorescence
staining data supported that ROS levels increased in MDSCs
in shControl tumors as compared to shCCL2 tumors (p <
0.00001) (Figure 5A). Using flow cytometry, we found that
PMN-MDSCs from shControl tumors showed significantly higher250 Cell Reports 12, 244–257, July 14, 2015 ª2015 The AuthorsROS levels as compared to shCCL2 tumors; this was not
observed for Mo-MDSCs (Figure 5B).
To determine the mechanisms by which CCL2 may influence
PMN-MDSC ROS production, we examined gp91phox and
p47phox, components of the Nox2 complex (Corzo et al.,
2009). PMN-MDSCs, but not Mo-MDSCs, from shControl
tumors had elevated gp91phox expression as compared to
shCCL2 tumors (Figure 5C). p47phox expression was very
low in both MDSC subsets, and there were no differences be-
tween shControl and shCCL2 tumors (Figure S5A). S100A8 and
S100A9, which promote MDSC accumulation (Sinha et al.,
2008), also participate in the formation of the Nox2 complex
(Cheng et al., 2008). PMN-MDSCs in shControl tumors had
significantly higher levels of S100A8 and S100A9 as compared
to shCCL2 tumors, while Mo-MDSCs expressed relatively low
levels (Figure 5D). These results are consistent with data sug-
gesting that oxidative stress is involved in MDSC-dependent
inhibition of T cell activation through the TCR. Hydrogen
peroxide (H2O2) and peroxynitrite (ONOO
) are produced by
the combined and cooperative activities of Nox2 complex,
Arg1, and iNOS. H2O2 leads to reduced TCR z chain expression
and peroxynitrite causes nitration of components of the TCR
signaling complex (Gabrilovich et al., 2012). We observed that
expression of nitrotyrosine significantly increased in CD8+
T cells co-cultured with PMN-MDSCs from shControl tumors
(Figure 4D). Next, we asked if Arg1 and iNOS affect the func-
tion of PMN-MDSCs in a CCL2-dependent manner. iNOS
expression, but not Arg1, increased in both PMN-MDSCs and
Mo-MDSCs from shControl versus shCCL2 tumors (Figures
5E and S5B). We also analyzed Arg1 and iNOS expression
in intratumoral TAMs and M2-like TAMs, but there were no
significant differences between shControl and shCCL2 tumors
(Figure S5C).
MDSCs in some tumor sites show differential expression of
PD-L1, and blockade of PD-L1 under hypoxic conditions abro-
gated MDSC-mediated suppression of T cells by modulating
MDSC cytokine production (Noman et al., 2014). There is now
a large body of preclinical and clinical data supporting that
blockade of T cell immune checkpoints can significantly
enhance antitumor immunity (Pardoll, 2012; West et al., 2013).
Given these data and the effects we observed of CCL2 on
MDSCs, we examined if CCL2 affected MDSC PD-L1 expres-
sion. In PMN-MDSCs from shCCL2 tumors, there was a modest
but not statistically significant decrease in PD-L1 expression as
compared to shControl tumors and no difference observed in
Mo-MDSCs (Figure 5F). Taken together, our data support that
CCL2 influences ROS production and expression of iNOS in
colon tumor PMN-MDSCs and affects MDSC-mediated sup-
pression of T cells via alterations to the TCR complex.
CCL2, via STAT3, Regulates PMN-MDSC
T-Cell-Suppressive Activity
Prior studies suggest that STAT3 controls MDSC accumulation
and suppressive activity via its transcriptional regulation of
myeloid cell differentiation and survival (Poschke et al., 2010;
Vasquez-Dunddel et al., 2013). In addition, both Nox2 and
S100A8/9 are upregulated in a STAT3-dependent manner
(Cheng et al., 2008; Corzo et al., 2009). To begin to resolve
whether CCL2 regulates PMN-MDSCs and if STAT3 may be
directly or indirectly involved, we analyzed intracellular phos-
phorylated (p-STAT3) levels in PMN-MDSCs. PMN-MDSC
pSTAT3 levels from shControl tumors were 4-fold higher than
those from shCCL2 tumors (Figures 6A and S6). C/EBPb is
another transcription factor that plays a critical role in regulating
MDSC differentiation and immunosuppressive activities (Lech-
ner et al., 2011; Marigo et al., 2010). However, C/ebpb expres-
sion was not different in either PMN-MDSCs or Mo-MDSCs
from shControl versus shCCL2 tumors (Figure 6B). To assess if
CCL2 was mediating its effects on intratumoral PMN-MDSCs
via STAT3, we treated sorted PMN-MDSCs from shControl
tumors with the STAT3 inhibitor S3I-201 and confirmed the
inhibition of p-STAT3 expression in PMN-MDSCs (Figure 6C).
Inhibition of STAT3 signaling in PMN-MDSCs reduced ROS
production, as well as expression levels of gp91phox, S100A8,
and S100A9 (Figures 6D–6G). We also observed decreased
iNOS expression in PMN-MDSCs treated with the STAT3 inhib-
itor (Figure 6H). Inhibiting STAT3 signaling with S31-201 reduced
PMN-MDSC suppression of T cell proliferation and led to
alterations in TCR z chain expression and tyrosine nitration (Fig-
ures 6I–6L). These results support that CCL2may be upstreamof
STAT3 activation and that activation of a CCL2-STAT3 pathway
may result in increased suppressive T cell activity through ROS
production and gp91phox and S100A8/9 expression in PMN-
MDSCs.
CCL2 Affects Adenoma Number and MDSC
Accumulation in ApcMin/+ Mice
Many sporadic CRCs begin as polyps or adenomas, which
are pre-cancerous tumors. Fewer than 10% of all adenomasbecome ACAs; however, more than 95% of CRCs develop
from adenomas. Therefore, identifying treatments for colorectal
adenomas to be given at or after their detection is an opportunity
for cancer prevention.
Given our results in human tissue samples, mouse models of
colitis-associated CRC, and a transplantable CRC model, we
examined the level of CCL2 in adenomas. In a human tissue
microarray, which included normal colon tissue (n = 38) and
adenomas (n = 40), CCL2 was significantly increased in ade-
nomas p < 0.05 (Figure 7A). With these data on increased
CCL2 in adenoma and published data showing that MDSCs
accumulate in human colorectal adenomas (Kimura et al.,
2013), we sought to determine if CCL2 would affect intestinal
tumor formation and alter intratumoral MDSCs in amousemodel
of intestinal adenomas. ApcMin/+mice develop small intestinal
adenomas with a high penetrance. This model is of preclinical
utility, as the APC gene is mutated in over 80% of human cancer
and human germline APC mutations are a cause of familial
adenomatous polyposis.
A prior study suggested thatCcl2/ ApcMin/+mice developed
fewer tumors (McClellan et al., 2012), and while this was a prom-
ising observation, such constitutive deletion has limited transla-
tional application to humans. We perturbed CCL2 by injecting
ApcMin/+micewith anti-CCL2 or isotype control monoclonal anti-
body (mAb). Antibody-mediated CCL2 neutralization reduced
small intestinal tumor numbers in ApcMin/+ mice (Figure 7B).
Intratumoral MDSC and PMN-MDSC numbers decreased in
tumors from ApcMin/+ mice treated with anti-CCL2 mAb, while
the number of intratumoral Mo-MDSC were not different (Fig-
ure 7C). Intratumoral PMN-MDSC ROS production significantly
decreased (Figure 7D). Given the trend we observed in CCL2-
mediated intratumoral MDSC PD-L1 levels in the Colon-26
model (Figure 5F), we examined PMN-MDSC PD-L1 expression
inApcMin/+ adenomas.We observed amodest decrease in PMN-
MDSC PD-L1 expression in adenomas from ApcMin/+ mice
treated with anti-CCL2 (Figure 7E). To confirm whether CCL2
was driving increased tumor number and MDSC accumulation
in this adenoma mouse model, we performed add-back experi-
ments wherein we intraperitoneally injected recombinant CCL2
or PBS into ApcMin/+ mice every 3 days for 4 weeks. Small intes-
tinal tumor numbers in ApcMin/+ mice treated with recombinant
CCL2 significantly increased (Figure 7F), as did intratumoral
MDSC and PMN-MDSC numbers (Figure 7G). We found a signif-
icant increase of PMN-MDSC PD-L1 expression in adenomas
from ApcMin/+ mice treated with recombinant CCL2 (Figure 7H).
These data support that CCL2 affects intestinal adenoma
numbers as well PMN-MDSC accumulation and function within
adenomas. These results, in conjunction with the data from the
other preclinical models studied herein, suggest that antibody-
mediated neutralization of CCL2 could be a potential therapeutic
for CRC prevention and interception.
DISCUSSION
Tumor-associated inflammation contributes to cancer growth
and spread, and intratumoral immune cells influence patient
prognosis and survival (Galon et al., 2013; Jochems and Schlom,
2011). While various immune cells and immunomodulatoryCell Reports 12, 244–257, July 14, 2015 ª2015 The Authors 251
Figure 6. CCL2, via STAT3, Regulates PMN-MDSC T-Cell-Suppressive Activity
(A) Phospho-STAT3 (p-STAT3) levels from PMN-MDSCs from shControl or shCCL2 tumors measured by flow cytometry. Mean ± SEM. **p < 0.001. Unpaired,
two-tailed Student’s t test.
(B) Expression of C/ebpb measured by qRT-PCR with data normalized to actin expression (mean relative expression ± SEM).
(C–H) Analysis of sorted intratumoral PMN-MDSCs from the mice with shControl tumors followed by treatment with a STAT3 inhibitor (S3I-201) (50 mM) for 18 hr.
Phospho-STAT3 (p-STAT3) levels (C) and ROS levels (DCFDA staining) (D), gp91phox (E) S100A8 (F), S100A9 (G) and iNOS (H) expression levels were measured.
Data are shown as mean ± SEM. *p < 0.05, **p < 0.01 (paired, two-tailed Student’s t test).
(I–L) Sorted intratumoral PMN-MDSCs from shCCL2 tumor-bearingmicewere treatedwith S31-201 and then coincubatedwith CD4+ T cells or CD8+ T cells. T cell
proliferation assays: CD4+ T cells (I) and CD8+ T cells (J) are shown. Division index represents T cell divisions. *p < 0.05, **p < 0.01 (paired, two-tailed Student’s
t test). z chain expression of CD4+ T cells (K) and nitrotyrosine levels of CD8+ T cells (L) measured by flow cytometry. All data represent two or three independent
experiments. *p < 0.05 (paired, two-tailed Student’s t test).
See also Figure S6.
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factors have been linked to increased cancer metastatic poten-
tial, identifying immune checkpoints at the earliest stages of can-
cer development and leveraging such discoveries to prevent
cancer development and progression has been a challenge
especially in CRC. Here, focusing on CCL2 in mouse models
of CRC, we demonstrate that CCL2 functions as a neoplastic
factor that regulates MDSC accumulation and function and
fosters a tumor permissive-microenvironment that influences
early-stage colon carcinogenesis. We also show that constitu-
tive deletion or antibody-mediated neutralization of CCL2 halts
neoplastic progression in an inflammation-associated CRC
model and APC-driven intestinal tumors in mice, respectively,
providing a rationale for the therapeutic potential of CCL2
inhibitors and neutralizing antibodies in CRC prevention and
treatment.
MDSCs have emerged as key effector cells in the tumormicro-
environment of many solid tumor malignancies, and our under-
standing of the factors that influence MDSC recruitment and
function continues to expand. For example, ACA-produced
granulocyte-macrophage colony-stimulating factor recruits
immature myeloid cells that accumulate in pancreatic ductal
ACAs in mice, thwarts CD8+T cell-mediated anti-tumor immu-
nity, and alters splenic MDSC proliferation and function (Bayne
et al., 2012). In the dextran sodium sulfate (DSS)-azoxymethane
(AOM) model of inflammation-associated CRC, loss of CXCR2
resulted in reduced tumor number, and CXCR2 expression on
MDSCs was a key underlying mechanism (Katoh et al., 2013).
Based on our data, CCL2 contributes to intratumoral MDSC
accumulation and also influences MDSC-mediated suppression
of CD4+ and CD8+ T cells via distinct pathways.
Several factors have been implicated in the T-cell-suppressive
activities of MDSCs. Our data support that CCL2 influences
PMN-MDSC ROS production via regulation of gp91phox,
S100A8, and S100A9, likely mediated by STAT3 activation.
While MDSC-produced ROS is known to influence TCR z chain
expression, our experiments enabled us to identify key compo-
nents of the pathway by which CCL2 regulates ROS production
in PMN-MDSCs. ROS play a myriad of roles in carcinogenesis
and influence not only cancer death and survival but also respon-
siveness to chemotherapy and radiation. Our data on ROS were
selectively focused on how CCL2 regulates ROS in PMN-
MDSCs and its subsequent role in suppressing T cells. We
observed that CCL2 also influences iNOS levels in both Mo-
MDSC and PMN-MDSCs. Tyrosine nitrosylation of the TCR
complex is another mechanism by which MDSCsmediated sup-
pression of T cells, and our data support that CCL2 plays a role
here. MDSCs utilize several overlapping mechanisms of sup-
pression and prior work has often focused on disrupting selec-
tive MDSC functions. In contrast, our study, which utilizes
multiple mouse models, unveils that CCL2 regulates several
suppressive functions of MDSCs with consequences for both
the innate and adaptive immune contribution to colorectal
tumorigenesis.
Our finding that CCL2 influenced early-stageCRC andMDSCs
rather thanmacrophages was unexpected given the literature on
CCL2 in human metastatic prostate cancer, metastatic breast
cancer (humans and mouse models), and the DSS-AOM model
(McClellan et al., 2012; Mizutani et al., 2009; Popivanova et al.,2009; Qian et al., 2011). Furthermore, our data that CCL2 pertur-
bations affected early-stage colorectal carcinogenesis both in
the presence and absence of macroscopic inflammation were
unanticipated, given the distinct molecular pathways underpin-
ning colitis-associated versus sporadic CRC (Clausen et al.,
2001; Itzkowitz, 2003).
Beyond immune cells in the tumor microenvironment contrib-
uting to carcinogenesis, the microbiota has also emerged as a
focus of recent interest (Garrett, 2015; Sears and Garrett,
2014). Fusobacterium nucleatum is a Gram-negative oral bacte-
rium that is enriched in colon cancers and adenomas (Castellarin
et al., 2012; Kostic et al., 2012; McCoy et al., 2013) and has
been associated with increased MDSC tumor infiltration in the
ApcMin/+ model in the absence of macroscopic inflammation
(Kostic et al., 2013). While the mice in this study did not harbor
F. nucleatum, it is notable that F. nucleatum elicits high levels
of CCL2 from the oral epithelium (Milward et al., 2007). Perhaps
CCL2 is a common node by which bacteria in tumors or cancer
cells themselves seek to evade immune destruction by enlisting
MDSCs.
Given the unanticipated nature of some of our findings
regarding CCL2’s effects on tumor development, we sought to
validate the clinical relevance and translational potential of our
findings by examining a small subset of human patients with
IBD-associated CRC, colon ACA tissuemicroarrays, and a colon
adenoma tissue microarray. Based on these human data, our
findings of antibody-mediated CCL2 neutralization in ApcMin/+
mice, and our experiments suggesting that there is a CCL2-
MDSC immune checkpoint at the earliest stage of CRC develop-
ment, more CCL2-directed therapies are warranted and merit
consideration in CRC prevention.
A recent study reported that CCL2 neutralization decreased
breast cancer metastases in mice, but interruption of CCL2 inhi-
bition led to increased metastases and decreased survival
(Bonapace et al., 2014). This study suggests that tumor type
and timing for a CCL2-directed therapy are critical and
more broadly highlights the dynamic nature of cancer’s respon-
siveness to a therapeutic. During some window of time, a partic-
ular therapy may be very beneficial, but as cancer evolves and
spreads, that same treatment may worsen cancer progression.
CCL2-directed therapies may indeed have a very specific thera-
peutic window. Our studies support that CCL2-neutralizing ther-
apies may play an important role in early-stage high-risk colon
cancer treatment and represent a promising application of
immunotherapy in colon cancer prevention.
Immunotherapies, to date, fall into three general categories:
cancer vaccines, adoptive cell therapies, and immune check-
point inhibitors (Allard et al., 2013; Pajtasz-Piasecka et al.,
2008). In the last few years, immune checkpoint inhibitors have
showed enormous promise in melanoma, renal cell cancer,
non-small cell lung cancer, and bladder cancer (Bailey and
McDermott, 2013; Langer, 2014; Ott et al., 2013). In particular,
antibodies targeting the PD-1, PD-L1, and CTLA4 checkpoints
appear very promising for these solid malignancies. However,
it remains to be determined why targeting these immune check-
point inhibitors is more efficacious in some solid tumor malig-
nancies versus others and in some, but not all, patients with
the same malignancy. Our findings that CCL2 influences theCell Reports 12, 244–257, July 14, 2015 ª2015 The Authors 253
(legend on next page)
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expression of PD-L1 in PMN-MDSCs and that CCL2 promotes
PMN-MDSC-mediated suppression of T cells raise the question
of whether intratumoral CCL2, PMN-MDSCs, and CCL2/PMN-
MDSC-mediated suppression of T cells may be important
factors to consider when determining why current immune
checkpoint therapies may not work for all patients. We sug-
gest that intratumoral or serum CCL2 and PMN-MDSC levels
may be useful to select patients for current immune check-
point therapies and that CCL2 neutralizing agents may be
needed to enhance responsiveness to current immune check-
point directed therapies in some patients. A caveat of our
work is that there may be differences between MDSCs
generated from human peripheral blood and mouse MDSCs
(Lechner et al., 2010). Future studies should be carried out in hu-
man colorectal adenomas and ACAs to better characterize




De-identified formalin fixed paraffin-embedded colonic tissue samples from
IBD patients with active colitis, LGD, HGD, and ACA were obtained from
Brigham and Women’s Hospital. Pathology was evaluated by G.S and R.O.
Animals and Tumor Models
All mice (BALB/c, BALB/c T-bet/ Rag2/, BALB/c Ccl2/T-bet/
Rag2/, and C57BL/6-ApcMin/+) were maintained in the barrier facility at the
Harvard T.H. Chan School of Public Health. For the generation of BALB/c
Ccl2/ T-bet/ Rag2/ mice, T-bet/ Rag2/ mice were bred to the
Ccl2/ mice on the BALB/cJ background, which were obtained from the
investigator who generated them (Prof. Barrett Rollins, Dana-Farber Cancer
Institute). Genotyping for Ccl2 was performed according to the instructions
from the vendor and for T-bet and Rag2 as previously described (Garrett
et al., 2007, 2009). Wild-type (WT) BALB/c mice (6–8 weeks) were bred in-
house and originally obtained from Jackson Laboratory. All mice are female.
All experimentation was carried out in accordance with institutional guidelines.
For the Colon-26 transplantation model, shControl or shCCL2 Colon-26 cells
(2 3 106) were subcutaneously injected into the flank of WT BALB/c mice
(6–8 weeks). For details on additional mousemodel experimentation, see Sup-
plemental Experimental Procedures.
Tissue Microarray Analysis
Arrays CO727 and CO2085b included both colon ACA and normal colon
tissue. Array CO809a included colon adenoma and normal colon tissue. For
details, see Supplemental Experimental Procedures.
Statistical Analysis
Student’s t test or the two-way ANOVA was performed using GraphPad Prism
software (version 6.0).Figure 7. CCL2 Affects Adenoma Number and MDSC Accumulation in
(A) CCL2 levels in human colon adenoma tissue microarrays (normal, n = 38; ad
(B–E) ApcMin/+ mice were injected with anti-CCL2 or isotype control mAb (10 mg
intestinal tumors from representative mice (left panel). Intestinal tumor counts fr
(C) MDSC, PMN-MDSC, and Mo-MDSC numbers from intestinal tumors from Ap
normalized by tumor weight. (D) ROS production levels (DCFDA staining) in intr
control mAb. (E) Expression of PD-L1 in intratumoral PMN-MDSCs from ApcM
cytometry.
(F–H) ApcMin/+ mice were injected with recombinant mouse CCL2 (20 mg/kg) fro
(F) Intestinal tumor counts. (G) Intestinal tumor MDSC, PMN-MDSC, and Mo-MD
mice treated with recombinant CCL2 or PBS measured by flow cytometry.
All data reflect at least three independent experiments. *p < 0.05 and **p < 0.01SUPPLEMENTAL INFORMATION
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